Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke "TIAS"


Phase 2 Results N/A

Summary of Purpose

Rationale The only proven therapy for acute stroke is tPA within 4.5 hours of symptom onset. This is the standard of care for patients presenting to our hospital within that time frame. Thrombolysis outside the 4.5 hour window is considered only on experimental or compassionate grounds. Tenecteplase (TNK) is a genetically modified variant of tPA that has many theoretical advantages in acute stroke. Studies show...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 4 April 2018.

1 Oct 2009 28 Mar 2014 1 Nov 2017 1 Nov 2017 1 Apr 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Non-Randomized
  • Masking: Open Label
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Single Group Assignment